Bone marrow mononuclear cells attenuate fibrosis development after severe acute kidney injury

Laboratory Investigation

Volumn 90, Issue 5, 2010, Pages 685-695

  Semedo, Patricia ^a   Donizetti Oliveira, Cassiano ^a   Burgos Silva, Marina ^a   Cenedeze, Marco Antonio ^a   Avancini Costa Malheiros, Denise Maria ^b   Pacheco Silva, Alvaro ^a   Camara, Niels Olsen Saraiva ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute kidney injury; Bone marrow; Fibrosis; Inflammation; Ischemia reperfusion injury; Mesenchymal stem cell

Indexed keywords

COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; HEME OXYGENASE 1; INTERFERON RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; FEMALE; FEMUR; FLUORESCENCE ACTIVATED CELL SORTING; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY ISCHEMIA; MONONUCLEAR CELL; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; TIBIA;

ACUTE DISEASE; ANIMALS; ANTIGENS, CD34; BONE MARROW CELLS; BONE MORPHOGENETIC PROTEIN 7; CELL TRANSPLANTATION; CELLS, CULTURED; CYTOKINES; FEMALE; FIBROSIS; GENE EXPRESSION; HEME OXYGENASE-1; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; ISCHEMIA; KIDNEY; KIDNEY DISEASES; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-KIT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77951802604     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.45     Document Type: Article

References (75)

1. Morgera S, Schneider M, Neumayer HH. Long-term outcomes after acute kidney injury. Crit Care Med 2008;36(4 Suppl):S193-S197.
2. Najafian B, Kasiske BL. Chronic allograft nephropathy. Curr Opin Nephrol Hypertens 2008;17:149-155.
3. Nankivell BJ, Borrows RJ, Fung CL, et al. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 2004;78:434-441.
4. Fletcher JT, Nankivell BJ, Alexander SI. Chronic allograft nephropathy. Pediatr Nephrol 2009;24:1465-1471.
5. Burne-Taney MJ, Yokota N, Rabb H. Persistent renal and extrarenal immune changes after severe ischemic injury. Kidney Int 2005;67:1002-1009.
6. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-1784.
7. Lee JM, Dedhar S, Kalluri R, et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006;172:973-981.
8. Zeisberg M, Kalluri R. Fibroblasts emerge via epithelial-mesenchymal transition in chronic kidney fibrosis. Front Biosci 2008;13:6991-6998.
9. Burns WC, Kantharidis P, Thomas MC. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs 2007;185:222-231.
10. Gore-Hyer E, Shegogue D, Markiewicz M, et al. TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol 2002;283:F707-F716.
11. Cheng O, Thuillier R, Sampson E, et al. Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am J Transplant 2006;6:2292-2306.
12. Chatziantoniou C, Dussaule JC. Is kidney injury a reversible process? Curr Opin Nephrol Hypertens 2008;17:76-81.
13. Yang J, Dai C, Liu Y. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 2002;13:2464-2477.
14. Nankivell BJ, Wavamunno MD, Borrows RJ, et al. Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant 2007;7:366-376.
15. Bloudickova S, Rajnoch J, Lodererova A, et al. Mycophenolate mofetil ameliorates accelerated progressive nephropathy in rat. Kidney Blood Press Res 2006;29:60-66.
16. Utimura R, Fujihara CK, Mattar AL, et al. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003;63:209-216. (Pubitemid 35463923)
17. Zeisberg M, Bottiglio C, Kumar N, et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol 2003;285: F1060-F1067.
18. Mitu G, Hirschberg R. Bone morphogenetic protein-7 (BMP7) in chronic kidney disease. Front Biosci 2008;13:4726-4739.
19. de Zeeuw D, Lewis EJ, Remuzzi G, et al. Renoprotective effects of renin-angiotensin-system inhibitors. Lancet 2006;367:899-900; author reply-2.
20. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002;136:604-615.
21. Bhagavati S. Stem cell based therapy for skeletal muscle diseases. Curr Stem Cell Res Ther 2008;3:219-228.
22. Roh JK, Jung KH, Chu K. Adult stem cell transplantation in stroke: its limitations and prospects. Curr Stem Cell Res Ther 2008;3:185-196.
23. Jing D, Parikh A, Canty JM, et al. Stem cells for heart cell therapies. Tissue Eng Part B Rev 2008;14:393-406.
24. English K, Barry FP, Field-Corbett CP, et al. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007;110:91-100.
25. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006;24:386-398.
26. Liu KD, Brakeman PR. Renal repair and recovery. Crit Care Med 2008;36(4 Suppl):S187-S192.
27. Humphreys BD, Bonventre JV. Mesenchymal stem cells in acute kidney injury. Annu Rev Med 2008;59:311-325.
28. Togel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005;289: F31-F42. (Pubitemid 40863570)
29. Semedo P, Wang PM, Andreucci TH, et al. Mesenchymal stem cells ameliorate tissue damages triggered by renal ischemia and reperfusion injury. Transplant Proc 2007;39:421-423.
30. Caldas HC, Fernandes IM, Gerbi F, et al. Effect of whole bone marrow cell infusion in the progression of experimental chronic renal failure. Transplant Proc 2008;40:853-855.
31. Goldberg R, Dennen P. Long-term outcomes of acute kidney injury. Adv Chronic Kidney Dis 2008;15:297-307.
32. Bell M. Acute kidney injury: new concepts, renal recovery. Nephron Clin Pract 2008;109:c224-c228.
33. Kinsey GR, Li L, Okusa MD. Inflammation in acute kidney injury. Nephron Exp Nephrol 2008;109:e102-e107.
34. Liu M, Liang Y, Chigurupati S, et al. Acute kidney injury leads to inflammation and functional changes in the brain. J Am Soc Nephrol 2008;19:1360-1370.
35. Scheel PJ, Liu M, Rabb H. Uremic lung: new insights into a forgotten condition. Kidney Int 2008;74:849-851.
36. Ko GJ, Rabb H, Hassoun HT. Kidney-lung crosstalk in the critically ill patient. Blood Purif 2009;28:75-83.
37. Kadkhodaee M, Golab F, Zahmatkesh M, et al. Effects of different periods of renal ischemia on liver as a remote organ. World J Gastroenterol 2009;15:1113-1118.
38. Goes N, Urmson J, Vincent D, et al. Acute renal injury in the interferon-gamma gene knockout mouse: effect on cytokine gene expression. Transplantation 1995;60:1560-1564.
39. Grigoryev DN, Liu M, Hassoun HT, et al. The local and systemic inflammatory transcriptome after acute kidney injury. J Am Soc Nephrol 2008;19:547-558.
40. Horikawa K, Takatsu K. Interleukin-5 regulates genes involved in B-cell terminal maturation. Immunology 2006;118:497-508.
41. Linfert D, Chowdhry T, Rabb H. Lymphocytes and ischemia-reperfusion injury. Transplant Rev (Orlando) 2009;23:1-10.
42. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res 2006;312:2169-2179.
43. Noel D, Djouad F, Bouffi C, et al. Multipotent mesenchymal stromal cells and immune tolerance. Leuk Lymphoma 2007;48:1283-1289.
44. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.
45. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-1822.
46. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838-3843.
47. Zhao ZG, Li WM, Chen ZC, et al. Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patients with chronic myeloid leukemia. Immunol Invest 2008;37:726-739.
48. Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007;109:228-234.
49. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-4621.
50. Togel F, Westenfelder C. Adult bone marrow-derived stem cells for organ regeneration and repair. Dev Dyn 2007;236:3321-3331. (Pubitemid 350276389)
51. Vitalone MJ, O'Connell PJ, Jimenez-Vera E, et al. Epithelial-to- mesenchymal transition in early transplant tubulointerstitial damage. J Am Soc Nephrol 2008;19:1571-1583.
52. Strutz FM. EMT and proteinuria as progression factors. Kidney Int 2008, Aug 20.
53. Maluf DG, Mas VR, Archer KJ, et al. Molecular pathways involved in loss of kidney graft function with tubular atrophy and interstitial fibrosis. Mol Med 2008;14:276-285.
54. Hertig A, Anglicheau D, Verine J, et al. Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 2008;19:1584-1591.
55. Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 2007;22:2011-2022.
56. Liu X. Inflammatory cytokines augments TGF-beta1-induced epithelial-mesenchymal transition in A549 cells by up-regulating TbetaR-I. Cell Motil Cytoskeleton 2008;65:935-944.
57. Higgins DF, Kimura K, Bernhardt WM, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007;117:3810-3820.
58. Bedi S, Vidyasagar A, Djamali A. Epithelial-to-mesenchymal transition and chronic allograft tubulointerstitial fibrosis. Transplant Rev (Orlando) 2008;22:1-5.
59. Park W, Griffin M, Grande JP, et al. Molecular evidence of injury and inflammation in normal and fibrotic renal allografts one year posttransplant. Transplantation 2007;83:1466-1476.
60. Chuang MJ, Sun KH, Tang SJ, et al. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci 2008;99:905-913.
61. Fan JM, Huang XR, Ng YY, et al. Interleukin-1 induces tubular epithelial-myofibroblast transdifferentiation through a transforming growth factor-beta1-dependent mechanism in vitro. Am J Kidney Dis 2001;37:820-831.
62. Copeland JW, Beaumont BW, Merrilees MJ, et al. Epithelial-to-mesenchymal transition of human proximal tubular epithelial cells: effects of rapamycin, mycophenolate, cyclosporin, azathioprine, and methylprednisolone. Transplantation 2007;83:809-814.
63. De Petris L, Hruska KA, Chiechio S, et al. Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol Dial Transplant 2007;22:3442-3450.
64. Dussaule JC, Chatziantoniou C. Reversal of renal disease: is it enough to inhibit the action of angiotensin II? Cell Death Differ 2007;14: 1343-1349.
65. Wang S, de Caestecker M, Kopp J, et al. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006;17:2504-2512.
66. Zeisberg M. Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol Dial Transplant 2006;21:568-573.
67. Patel SR, Dressler GR. BMP7 signaling in renal development and disease. Trends Mol Med 2005;11:512-518.
68. Biyikli NK, Tugtepe H, Cakalagaoglu F, et al. Downregulation of the expression of bone morphogenetic protein 7 in experimental pyelonephritis. Pediatr Nephrol 2005;20:1230-1236.
69. Dube PH, Almanzar MM, Frazier KS, et al. Osteogenic protein-1: gene expression and treatment in rat remnant kidney model. Toxicol Pathol 2004;32:384-392.
70. Zeisberg M, Kalluri R. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol 2008;23:1395-1398.
71. Neilson EG. Setting a trap for tissue fibrosis. Nat Med 2005;11:373-374.
72. Feitoza CQ, Goncalves GM, Semedo P, et al. Inhibition of COX 1 and 2 prior to renal ischemia/reperfusion injury decreases the development of fibrosis. Mol Med 2008;14:724-730.
73. Camara NO, Soares MP. Heme oxygenase-1 (HO-1), a protective gene that prevents chronic graft dysfunction. Free Radic Biol Med 2005;38:426-435.
74. Kim JH, Yang JI, Jung MH, et al. Heme oxygenase-1 protects rat kidney from ureteral obstruction via an antiapoptotic pathway. J Am Soc Nephrol 2006;17:1373-1381.
75. Kie JH, Kapturczak MH, Traylor A, et al. Heme oxygenase-1 deficiency promotes epithelial-mesenchymal transition and renal fibrosis. J Am Soc Nephrol 2008;19:1681-1691.